Erratum: Ezrin in primary cutaneous melanoma (Modern Pathology (2005) 18 (503-510) 10.1038/modpathol.3800300);Ezrin in primary cutaneous melanoma

Modern Pathology

Volumn 18, Issue 4, 2005, Pages 503-510

  Ilmonen, Suvi ^a,c   Vaheri, Antti ^b   Asko Seljavaara, Sirpa ^a   Carpen, Olli ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Toolo Hospital   (Finland)

Author keywords

ERM protein; Ezrin; Immunohistochemistry; Melanoma; Metastasis; Prognostic factor

Indexed keywords

EZRIN;

ADULT; AGED; ARTICLE; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOSKELETON; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN LYMPHOMA;

EID: 16444370230     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800429     Document Type: Erratum

References (54)

1. Breslow A. Thickness, cross-sectional area, and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-908.
2. Balch CM, Houghton AN, Sober AJ, et al. Cutaneous Melanoma, 4th edn. Quality Medical Publishing: St. Louis, MO, 2003.
3. Ruiter DJ, Spatz A, van der Oord JJ, et al. Pathologic staging of melanoma. Semin Oncol 2002;29:370-381.
4. Clark Jr WH, From L, Bernandino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-726.
5. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54:131-149.
6. Rogers GS, Braun SM. Prognostic factors. Dermatol Clin 2002;20:647-658.
7. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative mapping for early stage melanoma. Arch Surg 1992;127:392-399.
8. Slingluff CL, Vollmer RT, Reintgen DS, et al. Lethal 'thin' malignant melanoma. Identifying patients at risk. Ann Surg 1988;208:150-161.
9. Naruns P, Nizze J, Corchan A, et al. Recurrence potential of thin malignant melanoma. Cancer 1986;57:545-548.
10. Mangini J, Li N, Bhawan J. Immunohistochemical markers of melanocytic lesions. Am J Dermatopathol 2001;24:270-281.
11. Li N, Mangini J, Bhawan J. New prognostic factors of cutaneous melanoma: a review of the literature. J Cutan Pathol 2002;29:324-340.
12. Yaziji H, Gown AM. Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol 2003;11:11-15.
13. Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognostic significance of protein S-100β, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the folllow-up of high-risk melanoma patients. Cancer 2003;97:1737-1745.
14. Boni R, Doguoglu A, Burg G, et al. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996;35:416-418.
15. Vogt T, Zipperer K-H, Vogt A, et al. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997;30:57-63.
16. Ramsay JA, From L, Iscoe NA, et al. Mib-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995;105:22-26.
17. Hazan C, Melzer K, Panageas KS, et al. Evaluation of the proliferation marker Mib-1 in the prognosis of cutaneous malignant melanoma. Cancer 2002;95:634-640.
18. Agarwal ML, Taylor WR, Chernov MV, et al. The p53 network. J Biol Chem 1998;273:1-4.
19. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumor-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-416.
20. Weiss J, Heine M, Körner B, et al. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol 1995;133:23-31.
21. Stone CH, Lynch EF, Linden MD, et al. Immunocytochemical evaluation of proliferating cell nuclear antigen, Ki-67 (Mib-1), and p53 in predicting survival of primary and metastatic malignant melanomas. Appl Immunohistochem Mol Morphol 1996;4:25-33.
22. Cerroni L, Soyer HP, Kerl H. Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995;17:7-11.
23. Ramsay JA, From L, Kahn HJ. Bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995;8:150-154.
24. van den Oord JJ, Vandeghinste N, De Ley M, et al. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994;145:294-300.
25. Gould KL, Bretscher A, Esch FS, et al. cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1. EMBO J 1989;8:4133-4142.
26. r 75,000 protein. cDNA sequence, prokaryotic expression, and chromosomal localization. J Biol Chem 1989;264:16727-16732.
27. Bretscher A, Reczek D, Berryman M. Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. J Cell Sci 1997;110:3011-3018.
28. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002;3:586-599.
29. Tsukita S, Yonemura S, Tsukita S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol 1997;9:70-75.
30. Vaheri A, Carpen O, Heiska L, et al. The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol 1997;9:659-666.
31. Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol 1999;11:109-116.
32. Turunen O, Wahlström T, Vaheri A. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol 1994;126:1445-1453.
33. Gautreau A, Poullet P, Louvard D, et al. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999;96:7300-7305.
34. Dransfield DT, Bradford AJ, Smith J, et al. Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J 1997;16:35-43.
35. Mackay DJ, Esch F, Furthmayr H, et al. Rho- and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrin/radixin/moesin proteins. J Cell Biol 1997;138:927-938.
36. Lugini L, Lozupone F, Matarrese P, et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Invest 2003;83:1555-1567.
37. Gutmann DH. Molecular insights into neurofibromatosis 2. Neurobiol Dis 1997;3:247-261.
38. Geiger KD, Stoldt P, Schlote W, et al. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumours but is absent in oligodendrogliomas. Am J Pathol 2000;157:1785-1793.
39. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as a key metastatic regulators. Nat Med 2004;10:175-181.
40. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-186.
41. Moilanen J, Lassus H, Leminen A, et al. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol 2003;90:272-281.
42. Mäkitie T, Carpen O, Vaheri A, et al. Ezrin as a prognostic indicator and its relationship to tumour characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sei 2001;42:2422-2449.
43. Böhling T, Turunen O, Jääskeläinen J, et al. Ezrin expression in stromal cells of capillary hemangioblastoma. An immunohistochemical survey of brain tumours. Am J Pathol 1996;148:367-373.
44. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004;10:201-204.
45. Vo HP, Lee MK, Crowe DL. α2β1 integrin signaling via the mitogen activated protein kinase pathway modulated retinoic acid-dependent tumor cell invasion and transcriptional downregulation of matrix metalloproteinase 9 activity. Int J Oncol 1998;13:1127-1134.
46. Orian-Rousseau V, Chen L, Sleeman JP, et al. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002;16:3074-3086.
47. Crepaldi T, Gautreau A, Comoglio PM, et al. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol 1997;138:423-434.
48. Recio JA, Merlino G. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Cancer Res 2003;63:1576-1582.
49. Cohen C, Zavala-Pompa A, Segueira JH, et al. Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002;8:3728-3733.
50. Koo HM, VanBrocklin M, McWilliams MJ, et al. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 2002;99:3052-3057.
51. Collisson EA, De A, Suzuki H, et al. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003;63:5669-5673.
52. Ichikawa T, Masumoto J, Kaneko M, et al. Moesin and CD44 expression in cutaneous melanocytic tumours. Br J Dermatol 1998;138:763-768.
53. Ohtani K, Sakamoto H, Rutherford T, et al. Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett 2002;179:79-86.
54. Akisawa N, Nishimori I, Iwamura T, et al. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 1999;258:395-400.